The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

December 4, 2020 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence graphicACR CONVERGENCE 2020—In 2018, James P. Allison, PhD, and Tasuku Honjo, MD, PhD, were named the winners of the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation.1 These researchers revealed some of the ways certain proteins function as brakes on the immune system and how releasing these brakes could unleash immune cells and allow them to attack cancerous tumors. These discoveries and the practical implementation of such insights have led to an entirely new field within oncology that uses immune checkpoint inhibitors (ICIs) to effectively treat malignancy in ways that were not possible just a few years ago. However, every coin has two sides, and that is perhaps the best way to describe a potential side effect of ICIs: immune-related adverse events (irAEs).

You Might Also Like
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • Checkpoint Inhibitors May Be Retried after Immune Adverse Event, with Close Monitoring
Also By This Author
  • Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Core Tenets of Cancer Immunotherapy
At ACR Convergence 2020, this topic was discussed in eloquent detail during the session titled Checkpoint Inhibitors: Past, Present and Future. Jedd Wolchok, MD, PhD, Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation and chief of the Immuno-Oncology Service at Memorial Sloan Kettering Cancer Institute, New York, described the core tenets of cancer immunotherapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Wolchok discussed the way ipilimumab augments T cell activation and proliferation by binding CTLA4, thereby blocking the inhibitory signal of this pathway. A different ICI, nivolumab, binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, thereby impairing PD-1 pathway-mediated inhibition of the immune response to such entities as tumor cells. These medications are now effective components of the treatment regimens for lung cancer, esophageal cancer and melanoma, among other malignancies. Unleashing the effects of the immune system in this manner allows immune-mediated toxicities to occur in various organ systems, creating the potential for significant morbidity and mortality.

The exact incidence of irAEs is not known, and varies based on ICI regimen and the type of cancer being treated, but, as a general rule, the frequency and severity of irAEs appear to be greatest among patients receiving ipilimumab/nivolumab combination therapy, when compared with monotherapy.2-4 Colitis and hypophysitis are more common in patients receiving CTLA-4 therapy, and arthritis, pneumonitis and thyroiditis are more frequently seen in patients on PD-1 therapy.5-7  

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Some of the key takeaways from Dr. Wolchok’s portion of the talk were: 1) irAEs are not uncommon; 2) it is incumbent upon oncologists to screen for and promptly recognize signs of irAEs; and 3) when detected, oncologists should work together with rheumatologists to understand the nature of the irAE in question and effectively treat and manage these issues.

Pages: 1 2 3 4 | Single Page

Filed Under: ACR Convergence, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, immune checkpoint inhibitor (ICI), Immune checkpoint inhibitors, immunotherapy

You Might Also Like:
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • Checkpoint Inhibitors May Be Retried after Immune Adverse Event, with Close Monitoring
  • Progress on Preventing Immune-Related Adverse Events

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)